Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $3.54, for a total value of $15,526.44. Following the completion of the sale, the director owned 43,171 shares of the company’s stock, valued at approximately $152,825.34. The trade was a 9.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Recursion Pharmaceuticals Price Performance
Shares of RXRX stock opened at $3.32 on Friday. The stock has a 50-day moving average price of $3.30 and a 200 day moving average price of $3.82. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -2.77 and a beta of 1.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company’s revenue was down 56.8% on a year-over-year basis. During the same period last year, the company earned ($0.50) earnings per share. Research analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
Key Headlines Impacting Recursion Pharmaceuticals
Here are the key news stories impacting Recursion Pharmaceuticals this week:
- Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
- Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
- Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
- Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale
Analyst Ratings Changes
RXRX has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen lowered Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Bank of America reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Morgan Stanley raised their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. reduced their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $8.10.
Check Out Our Latest Research Report on Recursion Pharmaceuticals
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?
- IREN’s 800MW Bet Flips the AI Power Switch
- CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip?
- Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor Test
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
